Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ANI Pharmaceuticals, Inc. (Nasdaq: ANIP), a diversified biopharmaceutical company focused on rare disease, generics, and branded therapeutics. Through these filings, investors can review how ANI reports its financial results, capital structure changes, and other material events related to its Rare Disease, Generics, and Brands businesses.
ANI frequently files Form 8-K current reports to disclose quarterly and year-to-date financial results, updated investor presentations, and other significant developments. For example, recent 8-K filings reference press releases announcing results for specific quarters, updated guidance, and the publication of investor presentations that describe the company’s strategy, segment performance, and focus on products such as Purified Cortrophin Gel and ILUVIEN. Other 8-K filings discuss matters like the conversion of Series A Convertible Preferred Stock into common shares and updates on litigation outcomes.
In addition to 8-Ks, investors can use this filings page to locate ANI’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide more detailed discussions of segment results, risk factors, product portfolios, and the company’s rare disease strategy. These periodic reports elaborate on how ANI’s Rare Disease, Generics, and Brands businesses contribute to overall performance and outline risks related to manufacturing, regulatory approvals, competition, and market conditions.
Filings related to equity and capital structure are also important for ANIP. For instance, the company has reported on the issuance and subsequent conversion of Series A Convertible Preferred Stock, including dividend terms and conversion conditions, and on the issuance of common shares upon conversion under exemptions from registration. Such disclosures help investors understand changes in outstanding securities and potential dilution.
Stock Titan enhances this information by offering AI-powered summaries of ANI’s key filings. These summaries highlight the main points from lengthy documents, such as revenue trends, segment performance, major product updates, and notable legal or corporate events. Users can quickly scan 10-Ks, 10-Qs, and 8-Ks, and then dive into the full text on EDGAR for deeper analysis. The filings page also surfaces information relevant to insider and security-holder activity where reported, enabling a more complete view of ANI Pharmaceuticals’ regulatory and financial disclosures.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice proposing resale of common stock. The filing lists 4,000 restricted shares dated 04/10/2024 and 3,312 shares tied to a stock option exercise dated 03/05/2026.
ANI Pharmaceuticals reported that Christopher Mutz, its Head of Rare Disease, sold 417 shares of common stock in an open-market transaction at $74 per share. After this sale, he directly owns 103,508 shares. The sale was made under a pre-established Rule 10b5-1 trading plan adopted by the reporting person.
ANI Pharmaceuticals senior vice president Ori Gutwerg reported an open-market sale of company stock. On March 3, 2026, he sold 2,060 shares of Common Stock at a price of $76.50 per share. After this transaction, he directly owned 84,782 common shares.
ANI Pharmaceuticals director Patrick D. Walsh reported an open-market sale of 6,000 shares of common stock at $74.23 per share on March 3, 2026. After this transaction, he directly holds 52,405 shares.
ANIP submitted a Form 144 notice reporting a proposed sale of 6,000 common shares through Morgan Stanley Smith Barney LLC. The filing lists restricted stock lots dated 04/27/2023 (1,698 shares), 05/23/2024 (3,865 shares) and 05/21/2025 (437 shares).
ANI Pharmaceuticals is highlighting strong recent growth and ambitious 2026 goals as it meets institutional investors and updates its investor presentation. Total net revenue reached $883 million in 2025, a 44% year-over-year increase, driven by both rare disease and generics.
Lead rare disease drug Cortrophin Gel generated $348 million in 2025 revenue, up 76%, while ILUVIEN contributed $75 million. Adjusted non-GAAP EBITDA was $230 million, up 47%, and adjusted non-GAAP diluted EPS was $7.89, a 52% increase.
For 2026, the company is guiding to $1.055–$1.115 billion in total net revenue and $275–$290 million in adjusted non-GAAP EBITDA, implying roughly low‑20% growth at the midpoint. Rare disease products are expected to provide about 60% of 2026 revenue, with Cortrophin Gel forecast at $540–$575 million and ILUVIEN at $78–$83 million. Adjusted non-GAAP diluted EPS is projected at $8.83–$9.34 and adjusted gross margin at 59.3%–60.3%.
The strategy centers on accelerating transformation into a leading rare disease company, including a new ~90-person commercial organization for acute gouty arthritis flares and continued investment in Phase 4 trials and real‑world evidence for Cortrophin Gel. The generics segment, with about $384 million in 2025 revenue, remains an important cash generator supported by three U.S. manufacturing sites and a pipeline targeting 10–15 launches annually. Year-end 2025 cash was $286 million with net leverage of about 1.5x, supporting ongoing investment and disciplined capital allocation.
Shanmugam Muthusamy reported acquisition or exercise transactions in this Form 4 filing.
ANI Pharmaceuticals director and executive Shanmugam Muthusamy received a grant of 11,116 shares of common stock as a restricted stock award. The award was granted on February 26, 2026 at $77.15 per share and will vest in four equal annual installments on the first, second, third and fourth anniversaries of that date.
After this grant, he directly holds 101,056 common shares. He also has indirect ownership over 431,920 shares held by Esjay LLC and 5,000 shares held by SS Pharma LLC, where he holds voting and dispositive power over the shares.
ANI Pharmaceuticals executive Thomas Andrew Rowland, SVP and Head of Established Brands, reported equity compensation activity in company common stock. On February 26, 2026, he acquired 6,021 shares as a restricted stock award at $77.15 per share. This award will vest in four equal annual installments on the first through fourth anniversaries of February 26, 2026.
On February 28, 2026, 628 shares were disposed of at $73.90 per share to cover tax withholding in connection with the vesting of 2,171 previously granted restricted shares. After these transactions, he directly holds 43,502 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals executive Christopher Mutz reported two equity-related transactions in company stock. On February 26, 2026, he acquired 21,306 shares of common stock through a restricted stock award that will vest in four equal annual installments on each anniversary of February 26, 2026.
On February 28, 2026, 2,221 shares of common stock were disposed of to cover tax withholding in connection with the vesting of 4,342 previously granted restricted shares, a transaction exempt under Rule 16(b)-3. After these transactions, Mutz directly owned 103,925 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals President and CEO Nikhil Lalwani reported two equity compensation events involving the company’s common stock. On February 26, 2026, he acquired 75,592 shares through a restricted stock award at $77.15 per share. According to the footnotes, this award will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 26, 2026, tying his compensation to multi‑year performance.
On February 28, 2026, Lalwani had 12,217 shares withheld at $73.90 per share as a tax-withholding disposition in connection with the vesting of 23,883 previously granted restricted shares. These shares were withheld for tax purposes and are exempt under Rule 16(b)-3, rather than being an open-market sale. After these transactions, his directly owned common stock holdings were reported at 434,166 shares following the award and 421,949 shares following the tax withholding.